Lantheus Holdings, Inc. with ticker code (LNTH) have now 8 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 130 and 110 calculating the mean target price we have $121.50. Given that the stocks previous close was at $64.81 and the analysts are correct then there would likely be a percentage uptick in value of 87.5%. Also worth taking note is the 50 day moving average now sits at $73.92 and the 200 day moving average is $73.87. The market cap for the company is 4.39B. The stock price is currently at: 64.1 USD
The potential market cap would be $8,223,245,861 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 130.82, revenue per share of 16.46 and a 8.4% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
